Killer T cells surround a cancer cell Source: Alex Ritter, Jennifer Lippincott Schwartz & Gillian Griffiths, NIH

With a series of high profile phase 3 cancer immunotherapy combination trials expected to readout throughout 2018, what can we expect given the promise they may offer?

While many people tend to assume that a doublet should produce more efficacy than monotherapy, this isn’t always the case and there’s also the risk of increased toxicities.

That said, are there any hints and learnings we can garner from preclinical and clinical research that might help us assess some of the underlying challenges inherent in these randomised controlled trials?

I say yes there are and here we take a look at a couple of important indicators that may help understand what to expect ahead of time.

To learn more from our conference commentary and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by